Kevin Brady Sells 3,400 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CFO Kevin Brady sold 3,400 shares of Medpace stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the completion of the transaction, the chief financial officer directly owned 12,830 shares in the company, valued at approximately $8,021,829.20. The trade was a 20.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Medpace Stock Down 1.0%

NASDAQ:MEDP opened at $614.06 on Wednesday. The firm has a market capitalization of $17.14 billion, a P/E ratio of 35.99, a P/E/G ratio of 2.77 and a beta of 1.15. The company has a fifty day moving average of $556.26 and a 200 day moving average of $492.77. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on MEDP shares. BMO Capital Markets increased their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 target price on Medpace in a report on Thursday, July 23rd. TD Cowen raised their price target on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Finally, Truist Financial lifted their price target on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $584.18.

Institutional Trading of Medpace

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Johnson Financial Group Inc. purchased a new position in shares of Medpace during the 2nd quarter worth approximately $27,000. Elyxium Wealth LLC purchased a new position in shares of Medpace in the 4th quarter valued at approximately $30,000. Jones Financial Companies Lllp bought a new stake in shares of Medpace during the second quarter valued at approximately $30,000. Allied Private Wealth LLC bought a new stake in shares of Medpace during the second quarter valued at approximately $31,000. Finally, Kilter Group LLC purchased a new stake in Medpace in the second quarter worth $31,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure.
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.”
• Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.